Countries Europe

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

 October 26, 2026 | News

Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

 October 26, 2026 | News

Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth

Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earn...

 October 23, 2026 | Company results

Therakos Secures EU MDR Approval for First-of-Its-Kind Therapy to Manage Cancer Immunotherapy Toxicities

Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced t...

 October 23, 2026 | News

Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeut...

 October 22, 2026 | News

AstraZeneca and Oracle Join Forces to Harness AI and Real-World Data for Smarter Clinical Trials

Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelera...

 October 21, 2026 | News

Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy

 Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening...

 October 13, 2026 | News

12 APAC-Originated Programmes to Watch at ESMO 2026

When the ESMO Congress 2026 opens at IFEMA Madrid on Friday 23 October, the region that most European oncologists still think of as a fast follower will ho...

 October 13, 2026 | News

OncoBayes’ OB-001 Shows Potential to Overcome ADC Resistance and Boost Brain Penetration of Cancer Drugs

OncoBayes, a privately held clinical-stage pharmaceutical company, announced the successful completion of preclinical work with OB-001, demonstrating the p...

 October 08, 2026 | News

Bausch + Lomb Advances Oral Dry AMD Therapy BL1243 Following FDA Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced progress i...

 October 08, 2026 | News

QIAGEN Expands AI Push with New Tools for Biological Research and Drug Discovery

New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results New QIAGEN D...

 October 08, 2026 | News

EpiSign, Geneyx Partner to Integrate Genomic and Epigenomic Analysis for Rare Diseases

Collaboration brings EpiSign's comprehensive DNA methylation episignature analysis together with the Geneyx genomic and multi-omics analysis platform EpiS...

 October 07, 2026 | News

Genmab’s Rina-S Shows Durable Response in Platinum-Resistant Ovarian Cancer

Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median durat...

 October 06, 2026 | News

Lonza and Asimov Partner to Advance Lentiviral Vector Manufacturing for In Vivo Therapies

Collaboration connects Asimov’s genetic design and cell line technologies with Lonza’s process development, scale-up and GMP manufacturin...

 October 05, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close